BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2210
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension ; volume:7 ; number:1 ; day:25 ; month:7 ; year:2007 ; pages:1-2 ; date:7.2007
BMC pharmacology ; 7, Heft 1 (25.7.2007), 1-2, 7.2007
- Creator
-
Ghofrani, Hossein Ardeschir
Weimann, Gerrit
Frey, Reiner
Voswinckel, Robert
Thamm, Melanie
Bölkow, Desire
Weissmann, Norbert
Mück, Wolfgang
Unger, Sigrun
Wensing, Georg
Schermuly, Ralph Theo
Grimminger, Friedrich
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1471-2210-7-S1-S8
- URN
-
urn:nbn:de:101:1-2019062202454009457984
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ghofrani, Hossein Ardeschir
- Weimann, Gerrit
- Frey, Reiner
- Voswinckel, Robert
- Thamm, Melanie
- Bölkow, Desire
- Weissmann, Norbert
- Mück, Wolfgang
- Unger, Sigrun
- Wensing, Georg
- Schermuly, Ralph Theo
- Grimminger, Friedrich
- SpringerLink (Online service)
Other Objects (12)
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile
BAY 58–2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
Man Has Man Has Always
Has
Has
HAS
HAS
HAS
Has
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile
BAY 58–2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
Man Has Man Has Always
Has
Has
HAS
HAS
HAS
Has
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile
BAY 58–2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
Man Has Man Has Always
Has
Has
HAS
HAS
HAS